Back to Results

Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT00332189

Condition

Phenylketonuria

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

The objective of this study is to evaluate the safety of long-term treatment with Phenoptin in subjects with phenylketonuria (PKU) who participated in Phase 3 clinical studies with Phenoptin.

Eligibility Criteria

Birth Sex

All

Age

From 4 Years

Healthy Volunteers

No

Drug/Treatment:

sapropterin dihydrochloride

Phase:

Phase 3

Study Type:

Interventional

Number of Participants:

111

Study Started:

2006-07

Study Updated:

2012-11-16

Trial Locations

  • Los Angeles, California, United States

  • Sacramento, California, United States

  • San Jose, California, United States

  • New Haven, Connecticut, United States

  • Atlanta, Georgia, United States

  • Chicago, Illinois, United States

  • Minneapolis, Minnesota, United States

  • St. Louis, Missouri, United States

  • New York, New York, United States

  • Portland, Oregon, United States

  • Dallas, Texas, United States

  • Salt Lake City, Utah, United States

  • Seattle, Washington, United States

  • Madison, Wisconsin, United States

Inclusion Criteria

  • Participation in study PKU-004 or PKU-006
  • Willing and able to provide written, signed informed consent or, in the case of subjects under the age of 18 years, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures
  • Negative urine pregnancy test at screening (females of child-bearing potential)
  • Willing and able to comply with all study procedures

Exclusion Criteria

  • Non-responsive to prior treatment with Phenoptin based on participation in PKU-004 or PKU-006
  • Perceived to be unreliable or unavailable for study participation or, if under the age of 18 years, have parents or legal guardians who are perceived to be unreliable or unavailable
  • Terminated early from PKU-004 or PKU-006, except for subjects in PKU-004 that rolled into PKU-008 at Week 22, subjects in PKU-006 that rolled into PKU-008 at Week 10, or subjects in PKU-006 that terminated due to elevated Phe levels following dietary Phe increases
  • Use of any investigational product other than Phenoptin within 30 days prior to screening, or anticipated requirement for any investigational agent prior to completion of all scheduled study assessments
  • Positive urine pregnancy test at screening (non-sterile females of child-bearing potential only), already known to be pregnant or breastfeeding or planning a pregnancy in self or partner during the study
  • Female subjects of childbearing potential must be using an effective method of birth control, as determined by the PI, and willing to continue to use acceptable birth control measures
  • Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes)
  • Any condition that, in the view of the PI, renders the subject at high risk from treatment compliance and/or completing the study
  • ALT > 2 times the upper limit of normal (i.e., Grade 1 or higher based on World Health Organization Toxicity Criteria) at screening (see Appendix 2)
  • Serious neuropsychiatric illness (e.g., major depression) not currently under medical control
  • Prior history of organ transplantation
  • Requirement for concomitant treatment with any drug known to inhibit folate synthesis (e.g., methotrexate)
  • Concurrent use of levodopa
  • Clinical diagnosis of primary BH4 deficienc

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us